In leading the imaging component of oncology studies for Calyx’s global customers, Oliver leverages his experience from supporting over 600 clinical trials – with various indications, complexities, and in all phases of development – which led to the approval of over 20 oncology treatments. He is co-author of the immune-related response criteria (irRC, 2009), first author of irRECIST (2014), and co-author of Comparison of Assessments using RECIST and irRECIST by Manitz J. et al. (2020).

Leveraging her training in medicine and radiology, Surabhi has led the imaging components of approximately 50 oncology trials – both solid tumors and hematology malignancies – and provided consultation on complicated aspects of standardized response assessment criteria. Her expertise in Multiple Myeloma, Lymphoma, and CLL enables her to provide clear guidance to clinical trial sponsors and communicate complexities of criteria to independent reviewers to avoid heterogeneity.

Manuela is responsible for providing scientific advice on implementing medical imaging into clinical trials, conducting investigator, internal staff, and independent reviewer trainings, supporting the development of independent review charters, providing guidance to R&D and application development in the customization of image analysis software tools, and monitoring independent reviewer performance. Manuela has significant experience in leading and managing the imaging component of multiple neurology and oncology clinical trials, with expertise in applying neuro-oncology image assessment criteria such as RANO, iRANO, LANO, REiNS and volumetric analysis.

In his present role as Neurology Therapeutic Lead, Dr. Rohit Sood has contributed as a scientific lead on over 160 imaging clinical trials spanning the entire spectrum, from early to late phase, across multiple therapeutic areas including more than 40 in neurological indications. He has contributed to the science on several Neuro-oncology, Neurodegenerative, Neuropsychiatry and Rare disease clinical trials and has collaborated with our study sponsors to develop criteria for evaluating the eligibility, efficacy, and safety aspects of their studies. As a senior member of several scientific organizations and societies, Dr. Sood is actively engaged in furthering the science in the clinical trial space.

As a Principal Scientist at Calyx, Alice Motovylyak leverages her extensive knowledge in CNS disorders, including Alzheimer’s disease and spinal cord injury, as she designs and implements workflows for clinical trials involving imaging-based endpoints in these areas. To this end, she is involved in all study-related aspects including image acquisition, review design, development of independent reviewer charters, analysis application development, and independent reviewer training. Prior to joining Calyx, Alice was a post-doctoral researcher at the Alzheimer’s Disease Research Center (ADRC) at the University of Wisconsin where she focused on imaging biomarkers of aging and understanding how aging and risk factors of Alzheimer’s disease influence brain structure using diffusion weighted imaging.

Elif provides scientific oversight for clinical trials utilizing imaging across CNS indications including neuro-oncology, neuro-degenerative diseases, neuro-psychiatry and rare diseases. She has significant experience in consulting on imaging-based clinical trial endpoint determination and operationalization. She leads the development and the standardization of complex image acquisition guidelines, and has been instrumental in the development and the implementation of imaging assessment criteria and analysis methods, working extensively with key-opinion-leaders. She has initiated and has developed key partnerships to enhance Calyx’s CNS offerings particularly integrating quantitative analysis and AI. Prior to joining Calyx, Elif was a post-doctoral researcher at University of Massachusetts (UMASS) Medical School Psychiatry department where she worked on application of advanced MRI modalities for neuropsychiatric diseases in clinical populations as well as translational pre-clinical models.

Rudresh’s expertise in managing the imaging components of more than 200 oncology and haemato-oncology clinical trials resulted in the submission and approval of more than 20 regional and global oncology indication treatments. Building strong teams in the USA and APAC, he manages the USA, China, and Japan markets’ unique drug development challenges. A board-certified Radiologist, Rudresh serves as Co-Chair of a CT Coordinating Committee and CT Volumetry Biomarker Committee in QIBA, RSNA.

Farhan applies his extensive training and knowledge in bone loss mechanisms and imaging ‒ both in pre-clinical and clinical settings ‒ to leading and overseeing varied clinical trials involving the musculoskeletal system. He also serves as a subject matter expert in this area, contributing and facilitating protocol reviews as well as imaging-focused discussions with clients as well as consultation and networking with Key Opinion Leaders in the field.

As the Head of Calyx Musculoskeletal Imaging, Dr. Warner applies her 25+ years of medical imaging research experience and the expertise she’s gleaned from supporting over 200 imaging trials to help pharmaceutical companies and CROs succeed. She holds certifications by the International Society for Clinical Densitometry (ISCD) as a Clinical Densitometrist and a DXA technologist as well as a Radiology Practicing Technologist License in the state of Utah. Dr Warner’s musculoskeletal research has included the use of many different modalities for the assessment of bone metabolism including bone histomorphometry, 3-point bending, radiography, ultrasound, DXA, QCT, and high-resolution CT imaging.